30
Participants
Start Date
May 16, 2025
Primary Completion Date
June 1, 2027
Study Completion Date
June 1, 2028
Arm 1: Adebrelimab Combined with Chemoradiotherapy Followed by Surgery
"* Adebrelimab: Given concurrently with chemotherapy, 1200mg by intravenous infusion every three weeks for four cycles.~* Chemotherapy: Oxaliplatin 130mg/m² on day 1 + Capecitabine 1000mg/m² bid (XELOX regimen), from day 1 to day 14, repeated every three weeks for four cycles;~* Radiotherapy: Unresectable limited metastatic lesions with SBRT; Potentially resectable lesions with low-dose radiotherapy.~* Surgery: Performed 3-5 weeks after the completion of conversion therapy."
RECRUITING
Jiangsu cancer hospital, Nanjing
Jiangsu Cancer Institute & Hospital
OTHER